- Home
- DYAI vs KALA Comparison
DYAI vs KALA Comparison
Compare DYAI & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYAI
- KALA
- Stock Information
- Founded
- DYAI 1979
- KALA 2009
- Country
- DYAI United States
- KALA United States
- Employees
- DYAI N/A
- KALA N/A
- Industry
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- DYAI Health Care
- KALA Health Care
- Exchange
- DYAI Nasdaq
- KALA Nasdaq
- Market Cap
- DYAI 28.3M
- KALA 26.2M
- IPO Year
- DYAI 2004
- KALA 2017
- Fundamental
- Price
- DYAI $0.98
- KALA $5.86
- Analyst Decision
- DYAI Strong Buy
- KALA Strong Buy
- Analyst Count
- DYAI 1
- KALA 3
- Target Price
- DYAI $6.00
- KALA $14.00
- AVG Volume (30 Days)
- DYAI 63.9K
- KALA 118.3K
- Earning Date
- DYAI 08-12-2025
- KALA 08-05-2025
- Dividend Yield
- DYAI N/A
- KALA N/A
- EPS Growth
- DYAI N/A
- KALA N/A
- EPS
- DYAI N/A
- KALA N/A
- Revenue
- DYAI $3,554,344.00
- KALA N/A
- Revenue This Year
- DYAI $22.56
- KALA N/A
- Revenue Next Year
- DYAI $30.95
- KALA N/A
- P/E Ratio
- DYAI N/A
- KALA N/A
- Revenue Growth
- DYAI 57.59
- KALA N/A
- 52 Week Low
- DYAI $0.91
- KALA $2.92
- 52 Week High
- DYAI $2.20
- KALA $11.20
- Technical
- Relative Strength Index (RSI)
- DYAI 53.08
- KALA 60.68
- Support Level
- DYAI $0.91
- KALA $4.36
- Resistance Level
- DYAI $0.99
- KALA $7.00
- Average True Range (ATR)
- DYAI 0.06
- KALA 0.71
- MACD
- DYAI 0.01
- KALA 0.16
- Stochastic Oscillator
- DYAI 59.93
- KALA 63.97
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.